Showing results (351-360 of 379) with videos related to
Sort By:
Pageof 38
Nature Communications|April 26, 2020
Conditional deletion of Nedd4-2 in lung epithelial cells causes progressive pulmonary fibrosis in adult miceJulia Duerr, Dominik H W Leitz, Magdalena Szczygiel, et al.American Journal of Respiratory and Critical Care Medicine|March 18, 2021
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del AlleleEdith T Zemanick, Jennifer L Taylor-Cousar, Jane Davies, et al.The European Respiratory Journal|November 9, 2023
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension studyCori L Daines, Elizabeth Tullis, Stefano Costa, et al.Science Translational Medicine|December 8, 2022
Loss of endothelial CFTR drives barrier failure and edema formation in lung infection and can be targeted by CFTR potentiationLasti Erfinanda, Lin Zou, Birgitt Gutbier, et al.The New England Journal of Medicine|August 26, 2021
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function GenotypesPeter J Barry, Marcus A Mall, Antonio Álvarez, et al.American Journal of Respiratory and Critical Care Medicine|July 11, 2022
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled StudyMarcus A Mall, Rossa Brugha, Silvia Gartner, et al.The Lancet. Respiratory Medicine|January 5, 2025
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trialsClaire Keating, Lael M Yonker, François Vermeulen, et al.The Lancet. Respiratory Medicine|February 26, 2023
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trialsAhmet Z Uluer, Gordon MacGregor, Pilar Azevedo, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 2, 2026
Effects of Elexacaftor/Tezacaftor/Ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosisEva Van Braeckel, Andrew T Braun, Nicholas J Simmonds, et al.Science Translational Medicine|December 18, 2024
Dextromethorphan inhibits collagen and collagen-like cargo secretion to ameliorate lung fibrosisMuzamil M Khan, George Galea, Juan Jung, et al.Pageof 38